Behind the Drug Discounts: 340B, Medicare Negotiation, and Transparency Rory MartinandKatheryne Richardson June 18, 2026, 2:00 PM

https://www.healthaffairs.org/do/10.1377/he20260529.374685/full/ 18Jun20262:00PMEDT How do the Medicare Drug Price Negotiation and 340B programs intersect? Join Rory Martin of IQVIA and Katheryne Richardson of Second Sight Solutions, for insights on Medicare drug pricing, 340B transparency gaps, duplicate discounts, and evolving policy.